Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
about
Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1bSingle-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection deviceSubcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyUnderstanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices.Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional studyA patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate.Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population.Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and IrelandCutaneous Adverse Events Associated with Interferon-β Treatment of Multiple SclerosisAdherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyPatient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis.Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study.Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.A new electronic device for subcutaneous injection of IFN-β-1a.RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.Developing and testing a new instrument to measure women's satisfaction with controlled ovarian stimulation treatment.Autoinjector preference among patients with multiple sclerosis: results from a national survey.Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart® injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis.A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study.Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.Evaluation of performance, acceptance, and compliance of an auto-injector in healthy and rheumatoid arthritic subjects measured by a motion capture system.Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study).Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance
P2860
Q30406774-6A8A2CD4-0F08-4035-88B5-9000B0EDD401Q30839407-658AB99F-AB85-439A-B173-50951026D55FQ33774144-68ACA712-FEF7-4419-A8D2-FF1A4BC2A9BEQ34028864-7ED0E315-B9B1-4B59-B8EA-EC0A2BF05073Q34184837-949BE14B-C5C5-45F0-A2BF-B83AE5E3EFA9Q34957574-5BC99ABE-1AC6-4886-8D93-4404B8C86AC7Q35019187-3DA52F70-C653-4E33-8BC2-F08B274DFAABQ35100874-4C1798C0-9EBE-4075-9901-C0E203F6889AQ35604803-A8E600E3-4C27-4501-A6F2-BDF1547F9C21Q35703723-69FDE337-B871-471F-A292-0FA1856BAEA3Q35716870-2C46CC5B-4A37-4DB5-B30F-67F034099067Q35902459-3F269DB1-D4A9-48E3-8D24-884536BAAF32Q35948187-8664A415-2F63-4F04-807A-A012B8871C61Q36389706-B4FEB3DD-5532-4DA6-B041-4D7F7C3A2144Q37320927-9EBFE68D-B948-44A3-A3C1-1C4CCDA6F946Q37442175-68DF2E52-C46C-41B2-958F-AB47F1B9AAE2Q37597518-BDEB857E-2271-453D-B82C-BE1A8BFEFB6AQ37681428-EE7CD45C-B422-42C2-BC41-6C7EDD07F352Q37682836-93D11AB7-596B-416E-88BD-61F05F2BB977Q37897572-863CCB82-AF96-48A3-97C0-C9EEB6C60271Q38068514-C4DBE543-6DB0-4214-A607-13242DE85624Q38080149-F34DE22F-80C6-4240-B2A9-3E069762B230Q38613249-58A83367-6E86-411B-AE5C-B546B995174FQ38631863-9D36C47F-F5DC-4CB1-882C-42E613D9C34AQ38661416-D208BAE0-3981-44B7-AFA6-B66098538DDDQ38705140-01937A90-2B4D-4403-A28D-AC9C8A9E5DA8Q47282950-B5D29881-7B6A-4812-BACE-7428B963704FQ47574942-AE9351C4-2A59-4828-A19F-420CE1E46FDFQ48058748-393C8822-F2D1-470E-A8A0-BE3E9FB37F5CQ52576324-3E69C9A9-C4E1-43BF-A295-94D6E875024EQ53826589-9AE13137-A5C6-478B-9F8A-90DE5165D991Q59137067-9C22A9A0-1143-44A4-AC78-7808F323561B
P2860
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@ast
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@en
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@nl
type
label
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@ast
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@en
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@nl
prefLabel
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@ast
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@en
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@nl
P2093
P2860
P921
P356
P1433
P1476
Patient-rated suitability of a ...... multicentre, Phase IIIb study.
@en
P2093
Barry Singer
Bjorn Borre
Elisabetta Verdun di Cantogno
Michael Lang
Peter Cornelisse
Txomin Arbizu
Virginia Devonshire
P2860
P2888
P356
10.1186/1471-2377-10-28
P577
2010-04-30T00:00:00Z
P5875
P6179
1010891685